On January 25, 2024, the Board of Directors of Sunshine Biopharma, Inc. held its annual meeting. At the meeting the company elected Dr. Abderrazzak Merzouki as Chief Science Officer, Mr. Marc Beaudoin as Chief Operating Officer, and Mr. Malek Chamoun as Chief Development Officer. Previously, Dr. Merzouki had held the position of Chief Operating Officer.

Mr. Beaudoin and Mr. Chamoun are new officers. The other officers are continuing in their prior positions. Mr. Chamoun is also currently President of the Company?s wholly owned subsidiary, Nora Pharma Inc. The resumes of the Company?s new officers are as follows: Malek Chamoun, age 39,was appointed as Chief Development Officer in January 2024.

In 2017 he founded Nora Pharma Inc., a Canadian pharmaceutical company (?Nora Pharma?), based in Montreal, where he has been the President and CEO since inception. The company acquired Nora Phara in October 2022. Mr. Chamoun received a bachelor?s degree in business administration from Hautes Études Commerciales, Montreal, Quebec, Canada in 2008 and became a licensed CPA in Canada in 2012.

He devotes all of his business time to Nora?s affairs. Marc Beaudoin, age 57, was appointed as Chief Operating Officer in January 2024. Mr. Beaudoin has been self-employed as a business strategy consultant, primarily in the pharmaceutical and biopharmaceutical sectors, since 2016.

From 2006 to 2016, he held several executive positions at Sandoz Canada in various areas including Marketing and Communications, Strategic Planning, Business Development & Portfolio Management. As an executive and an entrepreneur, he combines expertise in strategic planning with operational and commercial execution. Mr. Beaudoin obtained his MBA from Sherbrooke University in 2018.

He also holds multiple certifications (including a fellowship) from the Association for Supply Chain Management.